Aforementioned above, our recent study along with others established the involvement of FOXM1 in SCLC growth and metastasis, revealing a promising platform to evaluate FOXM1 targeted therapies in SCLC progression. This evidence concerns the gene FOXM1 and small cell lung carcinoma.